A clinical evaluation of efficacy of bone graft material (Beta -tricalcium phosphate + hydroxyapatite) alone and in combination with platelet rich fibrin membrane in treatment of periodontal intrabony defects

SMBT DENTAL COLLEGE HOSPITA0 个研究点目标入组 20 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Intrabony defects in maxillary and mandibular arch
•2. Patients with two or more intrabony defects (Isolateral/contralateral) as well as isolated intrabony defects
•3. Intrabony defects (IBD)greater than or equal to 3 mm deep [distance between alveolar crest and base of the defect on intraoral periapical radiograph (IOPA)] along with an interproximal probing depth (PD) greater than or equal to 5 mm following phase I therapy
•4. Absence of overt clinical inflammation at the time of surgery
•5. Adequate amounts of interdental soft tissues
•6. Absence of any local anatomical limitations
•7. Patient willing for surgery and ready to give written consent

•1.Patients with systemic illness known to affect the outcomes of periodontal therapy, such as diabetes mellitus, cardiac diseases, platelet count less than 200,000/mm cube, or immunocompromised (e.g., HIV individuals) patients taking medications, such as corticosteroids.
•2.Individuals allergic to medications
•3.Pregnant or lactating women
•4.Patients using tobacco in any form
•5.Individuals with unacceptable oral hygiene (plaque index [PI] greater than 1.5).

发起方

SMBT DENTAL COLLEGE HOSPITA